This study was performed to clarify the dierent eects of each mutant exon of p53 as indicators of a poor prognosis in patients with non-small cell lung cancer (NSCLC). Tumor tissues of 204 patients with NSCLC were analysed; 96 tumors were stage I, 22 stage II, and 86 stage III. DNA was extracted from frozen specimens and polymerase chain reaction-single strand conformation polymorphism (PCR ± SSCP) and direct sequencing were performed to investigate mutations of p53 from exon 5 to exon 8. Seventy-®ve patients with NSCLC (36.8%) had mutations in p53 which included 72 cases of missense mutations and three cases of non-missense mutations. The overall survival rate of patients with mutant p53 adenocarcinomas was strikingly worse than that of patients whose tumors had wild-type p53 (35.7% vs 53.8%; P=0.041), but no signi®cant dierence in survival was found in the patients with NSCLC and squamous cell carcinoma. Mutations in exon 5 of p53 occurred in 33 cases (16.2%), mutation in exon 6 was detected in only one case (0.5%), mutations in exon 7 in 20 cases (9.8%), and mutations in exon 8 in 18 cases (8.8%). The overall survival rate of patients with mutations in exon 7 was worse than that of patients with wild-type p53 in NSCLCs and adenocarcinomas (42.9% vs 56.0%; P=0.025 and 33.3% vs 53.8%; P=0.048, respectively), whereas the overall survival of patients with mutations in exon 5 was almost the same as that of patients with wild-type p53. In addition, the overall survival rate of patients with mutations in exon 8 was strikingly worse than that of patients with wild-type p53 in NSCLCs, adenocarcinomas and squamous cell carcinomas (22.9% vs 56.0%; P50.001, 19.0% vs 53.8%; P=0.004 and 33.3% vs 62.5%; P=0.042, respectively). Multivariate analysis with the Cox regression model of patients with NSCLC, adenocarcinoma and squamous cell carcinoma indicated that mutations in exon 8 were best correlated with the overall survival rate, followed by lymph node status (P50.001, P=0.015 and P=0.006, respectively), and mutations in exon 7 of NSCLC were also revealed to have good correlation, followed by lymph node status and mutations in exon 8 (P=0.031). Mutation of p53 was a poor prognostic factor for adenocarcinoma as described previously. Moreover, mutations in exon 8 were more useful indicators of prognosis not only for adenocarcinoma but also for NSCLC. Worse overall survival of the patients with mutations in exon 8 of p53 was suggested to be associated with codon 273 mutations as well as mutations between codon 280 and 285 included into the H2 a helix corresponding to residues 278 ± 286. These results suggested that abnormal conformation of H2 a helix might play an important role not only in the loss of normal function but also in the acquisition of tumorigenesis. Investigation of mutations in exon 8, especially codon 273 mutation and mutant H2 a helix was considered to be a clinically useful approach for determining the prognosis of patients with NSCLC.
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Introduction
It is widely accepted that the p53 gene is a tumor suppressor gene (Levine et al., 1991; Vogelstein and Kinzler, 1992) and loss of normal function of p53 protein seems to cause carcinogenesis. Most nonfunctioning p53 proteins result from missense mutations of one p53 allele coupled to the deletion of the second allele. In fact, mutations of the p53 gene have been widely detected in various human cancers including lung cancer (Hollstein et al., 1991) . Recent studies have shown that p53 protein is associated with the cyclin dependent kinase (cdk) pathway (CordonCardo, 1995) . The p53 gene encodes a 53 kDa nuclear phosphoprotein with a transcriptional activator which controls cell proliferation by regulation of a G 1 -S checkpoint before DNA synthesis, while p53 induces cells to repair damage or promotes apoptosis (Yin et al., 1992; Hartwell, 1992; Farmer et al., 1992) . p21 is the major downstream target gene of p53 which is responsible for p53-induced G 1 arrest and which inhibits the protein kinase activities of G 1 cyclin/ CDK complexes, thereby preventing phosphorylation of the retinoblastoma (RB) protein, which leads in turn to inhibition of cell growth (Slebos et al., 1994) .
In addition, it has been reported that p53 is a prognostic factor for patients with cancer, including colorectal cancer (Zeng et al., 1994) , gastric cancer , breast cancer (Thor et al., 1992) , and non-small cell lung cancer (NSCLC) (Mitsudomi et al., 1993) . Several studies have assessed mutations of p53 as a prognostic factor for NSCLC (Quinlan et al., 1992; Horio et al., 1993; Ebina et al., 1994; Fukuyama et al., 1997) , but these results still remain controversial (McLaren et al., 1992; Passlick et al., 1995; Lee et al., 1995) . About 31 ± 55% of NSCLC are reported to contain mutations of the p53 gene and most of the p53 gene mutations are point mutations located in the region between exons 5 and 8 (Chiba et al., 1990; Greenblatt et al., 1994) , which contains the DNA binding site of the p53 protein ElDeiry et al., 1992) . To date, no study has reported which exon has the most important eect on the prognosis of the patients with NSCLC. In this study, we investigated mutations from exon 5 to exon 8 in 204 patients with NSCLC using polymerase chain reactionsingle strand conformation polymorphism (PCR ± SSCP) (Orita et al., 1989; Katsuragi et al., 1995) and direct sequencing, and revealed which mutant exon was most closely associated with prognosis in patients with NSCLC.
Results

Detection of total mutations of p53 in NSCLC by PCR ± SSCP
Of the 204 patients with NSCLC studied, 75 had carcinomas (36.8%) with mutations of p53 (Figure 1 ). Thirty-two tumors (26.2%) of the 122 patients with adenocarcinomas had mutations in p53. Thirty-four (47.9%) of the 71 patients with squamous cell carcinomas had mutations in p53. Nine (81.8%) of the 11 patients with large cell carcinomas had mutations in p53.
Relationship between gene mutations and known prognostic factors
Seventy-®ve cases with mutant p53 based on PCR ± SSCP results were analysed using DNA sequencing. Base changes and the clinical data of 75 cases are shown in Table 1 . All cases had point mutations, and three cases with non-missense mutations (cases 42, 56 and 66) were excluded from the mutant group and classi®ed into the wild-type group in the clinical analysis. Of the 204 total NSCLC studied, 72 carcinomas (35.3%) had mutations in p53. Twentynine tumors (23.8%) had mutations in p53 among the 122 adenocarcinomas. Thirty-four cases (47.9%) had mutations in p53 among the 71 squamous cell carcinomas. Nine cases (81.8%) had mutations in p53 among the 11 large cell carcinomas. Analysis of the 204 patients with NSCLC revealed that there were no statistically signi®cant relationships (chi-square test) between mutations of these genes and smoking habits, the patient's age at surgery, gender, tumor status, nodal status, and pathological stage. The only signi®cant relationship was found with tumor histology ( Table 2 ). The p53 mutation rate in adenocarcinomas was signi®cantly lower than that in squamous cell carcinomas (23.8% vs 47.9%, P50.001) and that in squamous cell carcinomas was signi®cantly lower than that in large cell carcinomas (47.9% vs 81.8%, P=0.036).
In addition, 33 tumors (16.2%) among the 204 NSCLCs had mutations in exon 5, but only one tumor had a mutation in exon 6. Twenty tumors (9.8%) had mutations in exon 7 and 18 tumors (8.8%) had mutations in exon 8 (Table 2 ). There was no signi®cant relationship between the distribution of mutant exons and prognostic factors.
Relationship between p53 mutations and tobacco smoking
Among 146 smokers with NSCLC, 56 cases (38.4%) had mutations in p53. Seventeen (30.4%) of the 56 smokers with mutant p53 had G : C to A : T transitions and 21 (37.5%) had G : C to T : A transversions. Twenty-four (16.4%) of 146 smokers with NSCLC had mutations in exon 5, 19 cases (13.0%) had mutations in exon 7 and 13 cases (8.9%) had mutations in exon 8. On the contrary, among 58 non-smokers with NSCLC, 16 non-smokers (27.6%) had mutant p53. Eight (50.0%) of 16 non-smokers with mutant p53 had G : C to A : T transitions and three cases (18.8%) had G : C to T : A transversions. Nine (15.5%) of the 58 non-smokers with NSCLC had mutations in exon 5 and ®ve cases (8.6%) had mutations in exon 8. Only one case (1.7%) had a mutation in exon 6 and exon 7. The rate of smokers with mutant exon 7 was signi®cantly higher than that of non-smokers (13.0% vs 1.7%, P=0.014).
Association of mutant exons of p53 with overall survival of NSCLC patients
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Association of mutant exons of p53 with overall survival of adenocarcinoma patients
There was a signi®cant dierence between the overall survival of patients with mutant p53 and those with wild-type p53 among the 122 adenocarcinomas (35.7%
vs 53.8%, P=0.041) as shown in Table 4) .
Association of mutant exons of p53 with overall survival of squamous cell carcinoma patients
There was no signi®cant dierence between the overall survival of the patients with mutant p53 and those with wild-type p53, but patients with mutations in exon 8 of p53 had signi®cantly worse overall survival than those with wild-type p53, as shown in Table 6 and Figure 4 (33.3% vs 62.5%, P=0.042). Especially, the overall survival of patients with mutations in exon 8 was signi®cantly worse among smokers, elderly patients (560 at surgery), males, and patients with stage I and N0 (P=0.031, P=0.021, P=0.047, P=0.047 and P=0.002 respectively). On the other hand, no signi®cant dierence was found in the overall survival of patients with mutations in exon 5 of p53 and those with mutations in exon 7. Cox regression analysis Figure 2 Overall survival of 204 patients with non-small cell lung cancer in relation to mutant exon status. Patients with mutations in exon 7 of p53 and those with mutations in exon 8 of p53 had signi®cantly worse overall survivals than those with wild-type p53 (*P=0.025 and **P50.001, respectively) revealed that two variables, mutations in exon 8 and nodal status were signi®cant prognostic factors of survival among patients with squamous cell carcinoma (P=0.006 and P50.001) ( Table 4) .
Discussion
Mutations in p53 widely occur in many types of human cancers (Takahashi et al., 1989) . More than 85% of the cancer-related mutations of p53 are missense mutations (Levine et al., 1994) . The majority of these mutations (more than 90%) occur in the core domain between codons 120 and 290 (from exon 5 to exon 8), which contains the sequence-speci®c DNA binding activity of the p53 protein, and these mutations result in loss of DNA binding activity (Velculescu and El-Deiry, 1996) . Mutations in p53 among patients with NSCLC are mainly point mutations, and most of these mutations are also located between exons 5 and 8 (Chiba et al., 1990) . Mutational hot spots include codons 175, 248, 273 and 281/282 (Greenblatt et al., 1994) . The most common base change in p53 mutations is the G : C to A : T transition in various types of cancers. Correlation of tobacco smoking with G : C to T : A transversion has also been reported (Greenblatt et al., 1994) . Among patients with NSCLC, the frequency of G : C to T : A transversion is relatively high, especially in smokers, and in patients with squamous cell carcinoma, as our results indicated. Recently, several studies have assessed the use of mutations in the p53 genes as a prognostic factor for NSCLC (Horio et al., 1993; Fukuyama et al., 1997) , but these results still remain controversial (McLaren et al., 1992; Passlick et al., 1995; Lee et al., 1995) . In the present study, we investigated which mutant exon had an eect on the prognosis for patients with NSCLC and revealed that mutations in exon 8 of p53 were signi®cantly associated with a poor prognosis not only in patients with adenocarcinoma but also those with squamous cell carcinoma, and in all patients with NSCLC. In addition, mutations in exon 7 of p53 was a poor prognostic factor for patients with adenocarcinoma. On the contrary, the survival of patients with mutations in exon 5 of p53 was almost as good as that of patients with wild-type p53. There are several possible reasons why p53 mutations are factors associated with a poor prognosis. The loss of normal function of wild-type p53 is one possibility, and the other is the acquisition of oncogenic characteristics of p53 (Hinds et al., 1990; Deb et al., 1992; Dittmer et al., 1993; Hann and Lane, 1995) . Some mutant p53 proteins can enhance reporter gene expression, which means that mutants may gain functions that can alter Figure 3 Overall survival of 122 patients with adenocarcinoma of the lung in relation to mutant exon status. Patients with mutations in exon 7 of p53 and patients with mutations in exon 8 of p53 had signi®cantly worse overall survivals than those with wild-type p53 (*P=0.048 and **P=0.004, respectively) gene expression (Dittmer et al., 1993) . Transfections of mutant codon 248, 249 or 273 into p53-null Jurkat cells enhanced the frequency of T-cell receptor surface expression (Iwamoto et al., 1996) . However, another study has reported that transfection of the codon 273-mutant p53 induced transactivation activity, while transfection of the codon 175-mutant and transfection of the codon 248-mutant did not induce transactivation activity (Park et al., 1996) . Because there are many various mutations of p53 with possible dierent functions (Hinds et al., 1990; Levine, 1992; Kawamura et al., 1996) , further investigations are required to clarify the mechanism of mutant p53 and make classi®cation of the functions of mutant p53. By the way, the worse overall survival of patients with mutations in exon 8 of p53 appeared to have an association with codon 273 mutation as well as mutations in the region between codons 280 and 285. Six (33.3%) of the 18 patients with mutations in exon 8 had codon 273 mutations and ®ve of six patients with codon 273 mutations were dead. Moreover, the region between codons 280 and 285 is included into an H2 a helix corresponding to residues 278 ± 286 and Arg 282 from the H2 a helix plays a structural role in the loopsheet-helix motif, being involved in the packing of the H2 a helix against the b hairpin and the L1 loop . Astonishingly, six (75.0%) of the eight patients with a mutant H2 a helix were already dead, suggesting that abnormal conformation of the H2 a helix might play an important role in not only the loss of normal function but also the acquisition of tumorigenesis. In addition, comparing the survival among 204 patients with NSCLC revealed that the overall survival rate for the 20 patients whose tumors had mutations in exon 7 of p53 was strikingly lower than that of the 132 patients with wild-type p53 tumors (42.9% vs 56.0%, P=0.025 respectively). However, only four of 10 patients with codon 248 or 249 mutations were dead and there was no signi®cant dierence between the overall survival rate of the 10 patients with codon 248 or 249 mutations and those with wild-type p53 (60.0% vs 56.0%). These results suggest that mutations in exon 7 had less important eects on prognosis of the patients with NSCLC than mutations in exon 8. Moreover, no dierence was detected between the overall survival of patients with mutations in exon 5 of p53 and those with wild-type p53 and all seven patients with a mutant codon 175 remain alive. Although Arg 175 occurs in the L2 loop in the vicinity of the zinc binding site, most of this part is buried away from the protein surface, so mutations in exon 5 would likely have no eect on the prognosis of patients with NSCLC.
Our study of the patients with NSCLC showed that of the four mutant exons studied, mutations in exon 8 Figure 4 Overall survival of 71 patients with squamous cell carcinoma of the lung in relation to mutant exon status. Only patients with mutations in exon 8 of p53 had signi®cantly worse overall survival than those with wild-type p53 (*P=0.042) of p53 were the most useful indicators of poor prognosis for both adenocarcinoma and squamous cell carcinoma patients. Mutations in exon 7 of p53 were also poor prognostic factors for the patients with adenocarcinoma. On the other hand, patients with mutations in exon 5 of p53 had almost the same survival rate as those with wild-type p53. Evaluation of exon 8 and exon 7 of p53 may be clinically valuable in the detection of high risk groups among patients with NSCLC. In addition, these results suggest the possibility of new tumorigenic functions of mutant exon 8 and mutant exon 7.
Materials and methods
Clinical characteristics of patients
From January 1991 to April 1995, the patients who underwent surgery at the Department of Surgery of the Center for Adult Diseases of Osaka and the Department of Thoracic Surgery of the Kitano Hospital, Medical Research Institute of Osaka in Japan, were studied. Tumor-node metastasis (TNM) staging designations were made according to the postsurgical pathological international staging system (Hermanek and Sobin, 1987) . Because advanced stage lung cancer (stage IV) involved several ill-de®ned factors and had distant metastases, these patients were excluded from this study. Patients with two or more forms of cancers and patients who died of causes other than lung cancer were also excluded from this study. In total, 204 patients with lung cancer up to stage III B, which included 122 patients with adenocarcinoma, 71 patients with squamous cell carcinoma, and 11 patients with large cell carcinoma, were investigated. Patients' clinical records and histo-pathological diagnoses were fully documented. This report includes follow-up data as of February 1 in 1997. The median follow-up period for all patients was 31.9+17.6 months. All patients with N2 or N3 status had mediastinal radiotherapy (50 Gy in 25 fractions for a period of 5 weeks) after surgical resection and then were treated by two cycles of adjuvant chemotherapy including cisplatin (80 mg per square meter of body-surface area given intravenously on day 1) and vindesine (4 mg per square meter of body-surface area given intravenously on days 1, 8 and 15). Eighteen patients with T3 or T4 status, who were found to have incomplete resection, also received radiotherapy (50 Gy in 25 fractions for a period of 5 weeks) for microscopic-positive margins. The other patients had no radiotherapy before recurrence. Post-operative adjuvant systemic chemotherapy was given according to nodal status. Of 82 node positive patients, 78 patients underwent treatment by the adjuvant chemotherapy with two cycles of cisplatin and vindesine. Of 122 node negative patients, 119 patients did not have any further adjuvant treatments. We detected distant metastases in 83 patients during the observation period, and among these 83 patients, 14 patients had also local recurrences. Seven patients had locoregional recurrences. After recurrence, locoregional tumors or lymph nodes were principally treated with radiotherapy. Patients with distant metastases were treated with more chemotherapy including cisplatin and etoposide.
Tumor specimens and DNA extraction
In order to ascertain the presence of cancer cells, one half of each fresh tumor tissue specimen was immediately embedded in optimum cutting temperature (OCT)-compound (Miles, Kankakee, IL) and frozen sections were cut on the cryostat to a thickness of 6 mm and immediately stained with hematoxylin and eosin. The other half of a given tumor specimen containing only cancer cells was frozen and stored at 7808C for subsequent DNA analysis. Genomic DNA was extracted from these specimens by using proteinase K digestion, followed by phenol/chloroform extraction and ethanol precipitation (Sambrook et al., 1989) .
PCR
Oligonucleotides were synthesized as partially intron-based PCR primers based on the published reports as follows (Katsuragi et al., 1995) Exon 5f of p53-5'TCT GTC TCC TTC CTC TTC CT-3': Exon 5r of p53-5'-TCT CCA GCC CCA GCT GCT-3': Exon 6f of p53-5'-TGA TTC CTC ACT GAT TGC TCT-3': Exon 6r of p53-5'-GAG ACC CCA GTT GCA AAC C-3': Exon 7f of p53-5'-TCT TGG GCC TGT GTT ATC TC-3': Exon 7r of p53-5'-AGG GTG GCA AGT GGC TCC-3': Exon 8f of p53-5'-GCT TCT CTT TTC CTA TCC TGA-3': Exon 8r of p53-5'-CGC TTC TTG TCC TGC TTG C-3'. The number in each designation indicates the region of the exon of the gene subjected to examination by PCR ± SSCP. The designatioǹ f' indicates a sense primer, and`r' indicates an antisense primer. Forty cycles of PCR ampli®cation were performed as follows: denaturation of 948C for 1 min, annealing at 608C for 1 min for exons 5, 6 and 7, and at 558C for exon 8, and extension at 728C for 1.5 min followed by ®nal extension at 728C for 7 min.
SSCP
Seven ml of PCR products was diluted with 10 ml of buer consisting of 20 mM EDTA, 96% deionized formamide, and 5 mg/ml Dextran Blue 2000. Heating denature was performed at 958C for 5 min, after which samples were placed on ice for 5 min. Then 16 ml of this solution was applied to each lane of a 7.5% neutral polyacrylamide gel. Electrophoresis was performed at 15 mA in buer at a temperature of 188C (3 h for exon 5, 2.5 h for exons 6, 7 and 8). The gel was stained with 2 mg/ml ethidium bromide and visualized under ultraviolet light (Figure 1 ).
Direct sequencing
In order to ascertain base changes and exclude the cases with non-missense mutations from mutant cases classi®ed with PCR ± SSCP, direct sequencing was performed using Chemiluminescent DNA sequencing kit (Toyobo, Osaka, Japan). Biotinylated primers of each exon, as described in the methods for PCR were synthesized for end-labeling.
Statistical analysis
Clinical data, including smoking habits, were extracted from clinical records. Smokers were de®ned as patients whose Brinkman index was greater than 400. Overall cancer speci®c survival was de®ned from the date of operation to the date of cancer related death. The statistical signi®cance of dierences in the incidence of mutations in exons of p53 and several clinical and pathological parameters was assessed by the chi-square test and the t-test. The Kaplan ± Meier method was used to estimate the probability of overall survival as function of time, and dierences in the survival of subgroups of patients were compared with Mantel's log-rank test (Kaplan and Meier, 1958; Mantel, 1966) . Multivariate analyses were performed using the Cox regression model to study the eects of dierent variables on survival (Cox, 1972) and eight factors (status of exon 5, exon 7 and exon 8, smoking habits, gender, age at surgery, T stage, and N stage) were studied. Mutation in exon 6 was excluded from factors of multivariate analyses because exon 6 mutation was detected in only one patient. Scores were assigned to each variable for the regression analysis. All P values are based on two-tailed statistical analysis and a P value 50.05 was considered to indicate statistical signi®cance.
